Glucagon-like peptide-1 based drugs for Type 2 diabetes do not pose new safety concerns, specifically in relation to an increased risk of pancreatic adverse events, the European Medicines Agency announced on 26 July 2013. ---Subscribe to MedNous to access this article--- Regulation & Policy
